Previous 10 | Next 10 |
2024-02-15 11:32:26 ET DENVER, Colo, Feb 15, 2024 ( 247marketnews.com )- ( NASDAQ:BMR ) ( NASDAQ:DTSS ) ( NASDAQ:CCCC )( NASDAQ:SIEN ) ( NASDAQ:BMR ) Beamer Imaging Inc. stock is bouncing off today’s low of $9.0 and has moved up to $10.78 on increasing vol...
USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine . As well, there are now alarming reports around the world of rising diagnoses of HIV, which is being linked to higher ana...
2024-01-29 13:58:34 ET More on C4 Therapeutics C4 Therapeutics: Merck News Does Not Make It A Buy Yet, But Upgrading To Hold C4 Therapeutics gains on restructuring plan C4 Therapeutics stock rallies on Merck deal to develop cancer antibodies Seeking Alpha...
2024-01-25 08:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-23 09:47:13 ET Bank of Montreal (FNGD) FNGD is trading DOWN for the last 4 days, and it at trading at $5.17 with volume of 1,660,669 and a one day change of $-0.07 (-1.34%). Bank of Montreal has a 52-week low of 5.10 and a 52-week high of $42.58. The business's 50-day moving...
2024-01-10 11:04:59 ET More on C4 Therapeutics C4 Therapeutics: Merck News Does Not Make It A Buy Yet, But Upgrading To Hold C4 Therapeutics stock rallies on Merck deal to develop cancer antibodies C4 Therapeutics gains as Morgan Stanley upgrades on Q3 updates ...
C4 Therapeutics, Inc. (NASDAQ: CCCC) is one of today's top gainers. The company's shares have moved 8.63% on the day to $1.51. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cance...
Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research Efforts Results in Workforce Reduction of Approximately 30% Una...
2024-01-09 01:05:44 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Cellectar Biosciences, Inc. (NASDAQ: CLRB), Aclarion, Inc. (NASDAQ: ACON), Ardelyx (NASDAQ: ARDX), Sidus Space Inc. (NASDAQ: SIDU), NexImmune Inc. (NASDA...
2024-01-08 07:53:16 ET The following companies are covered in this article, (NASDAQ: CCCC), Merck (NYSE: MRK), (NASDAQ: NEXI), (NASDAQ: SIDU), and (NASDAQ: SYTA) DENVER, Colo, January 8, 2024 ( www.247marketnews.com ) – The Trend is your friend and, when it comes to massive g...
News, Short Squeeze, Breakout and More Instantly...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidom...